Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Systemic therapy, gastrectomy, cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy versus systemic therapy alone for gastric cancer with limited peritoneal metastases (PERISCOPE II): final results of a multicentre, randomised, controlled, phase 3 trial after an unplanned commissioned interim analysis.

The Lancet. Oncology·2026
Same author

Perioperative systemic therapy versus surgery alone for resectable colorectal peritoneal-only metastases (CAIRO6): a randomised, open-label, phase 3 trial.

The Lancet. Oncology·2026
Same author

Hepatic artery infusion pump chemotherapy for unresectable intrahepatic cholangiocarcinoma: Pooled individual patient-level analysis of four clinical trials.

Journal of hepatology·2026
Same author

Total Neoadjuvant Treatment for Esophageal Adenocarcinoma With Oligometastases: TNT-OES-1 Trial.

International journal of cancer·2026
Same author

Imaging strategies for follow-up during adjuvant nivolumab in esophageal cancer: A multicenter retrospective cohort study.

PloS one·2026
Same author

Active surveillance for esophageal cancer after clinically complete response: relevant considerations of the SANO-trial.

Journal of thoracic disease·2026

Related Experiment Video

Updated: Aug 14, 2025

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
09:02

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

12.0K

Intraperitoneal Chemotherapy for Unresectable Peritoneal Surface Malignancies.

Niels A D Guchelaar1, Bo J Noordman2, Stijn L W Koolen3,4

  • 1Department of Medical Oncology, Erasmus MC Cancer Institute, Dr. Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands. n.guchelaar@erasmusmc.nl.

Drugs
|January 12, 2023
PubMed
Summary

Intraperitoneal chemotherapy offers a promising approach for unresectable peritoneal malignancies, overcoming systemic delivery limitations. Further research is needed to optimize treatment schedules and confirm its role alongside standard therapies.

More Related Videos

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma
09:52

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Published on: January 25, 2015

13.5K
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.5K

Related Experiment Videos

Last Updated: Aug 14, 2025

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
09:02

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

12.0K
Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma
09:52

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Published on: January 25, 2015

13.5K
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.5K

Area of Science:

  • Oncology
  • Surgical Oncology
  • Pharmacology

Background:

  • Malignancies of the peritoneal cavity have a poor prognosis.
  • Systemic chemotherapy's efficacy is limited by the peritoneal-plasma barrier.
  • Intraperitoneal chemotherapy presents a novel treatment strategy.

Purpose of the Study:

  • To systematically review drugs used in intraperitoneal chemotherapy.
  • To summarize clinical studies and complications of intraperitoneal chemotherapy.
  • To evaluate the potential of intraperitoneal chemotherapy for unresectable peritoneal disease.

Main Methods:

  • Systematic review of existing literature.
  • Analysis of clinical studies (Phase I, II, and III).
  • Evaluation of drug efficacy and safety profiles.

Main Results:

  • Taxanes (paclitaxel, docetaxel) are commonly used.
  • Phase I/II studies show promising results for various cancers (gastric, ovarian, colorectal, pancreatic).
  • Phase III studies in gastric cancer show contradictory results; Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) shows a tolerable safety profile.

Conclusions:

  • Intraperitoneal chemotherapy, particularly with taxanes, shows potential for unresectable peritoneal disease.
  • More Phase II/III studies are required to establish optimal treatment and confirm its role.
  • Further research should focus on tolerability, survival rates, and quality of life.